Empaveli (pegcetacoplan)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Key Facts
About bioRASI
bioRASI is a mission-driven CRO focused on bringing critical therapies to market through collaboration, operational discipline, and scientific excellence. The company has executed over 200 trials across 48 countries, with particular strength in therapeutic rescue scenarios and rare disease studies. Its strategic approach combines dedicated, accessible leadership teams with advanced data science capabilities and a culture of accountability, positioning it as a trusted partner for sponsors navigating high-stakes clinical development.
View full company profileAbout bioRASI
bioRASI is a mission-driven CRO focused on bringing critical therapies to market through collaboration, operational discipline, and scientific excellence. The company has executed over 200 trials across 48 countries, with particular strength in therapeutic rescue scenarios and rare disease studies. Its strategic approach combines dedicated, accessible leadership teams with advanced data science capabilities and a culture of accountability, positioning it as a trusted partner for sponsors navigating high-stakes clinical development.
View full company profileAbout bioRASI
bioRASI is a mission-driven CRO focused on bringing critical therapies to market through collaboration, operational discipline, and scientific excellence. The company has executed over 200 trials across 48 countries, with particular strength in therapeutic rescue scenarios and rare disease studies. Its strategic approach combines dedicated, accessible leadership teams with advanced data science capabilities and a culture of accountability, positioning it as a trusted partner for sponsors navigating high-stakes clinical development.
View full company profileTherapeutic Areas
Other Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
| Drug | Company | Phase |
|---|---|---|
| EMPAVELI/Aspaveli (pegcetacoplan) | Apellis Pharmaceuticals | Approved |
| OMS906 | Omeros Corporation | Phase 1 |